Table 5.
30‐day clinical outcomes in patients with and without PAD by anticoagulant type
| OUTCOMES | No PAD 682 (85%) | PAD 119(15%) | p‐value for interaction | ||||
|---|---|---|---|---|---|---|---|
| Bivalirudin 344 (50.4%) | UFH 338 (49.6%) | p‐value | Bivalirudin 60 (50.4%) | UFH 59 (49.6%) | p‐value | ||
| Death | 14 (4.1%) | 19 (5.6%) | .35 | 4 (6.7%) | 1 (1.7%) | .18 | .14 |
| NACE | 47 (13.7%) | 55 (16.3%) | .34 | 8 (13.3%) | 10 (17.0%) | .58 | .89 |
| CVA | 11 (3.2%) | 9 (2.7%) | .68 | 2 (3.3%) | 2 (3.4%) | .99 | .85 |
| AKI | 61 (17.7%) | 49 (14.5%) | .25 | 15 (25.0%) | 7 (11.9%) | .07 | .22 |
| VASC COMP | 66 (19.2%) | 52 (15.4%) | .19 | 23 (38.3%) | 12 (20.3%) | .031 | .181 |
| MAJOR VASC | 31 (9.0%) | 29 (8.6%) | .84 | 6 (10.0%) | 9 (15.3%) | .39 | .39 |
| MINOR VASC | 36 (10.5%) | 24 (7.1%) | .12 | 17 (28.3%) | 3 (5.1%) | .001 | .027 |
| BARC | 30 (8.7%) | 33 (9.8%) | .64 | 4 (6.7%) | 9 (15.3%) | .133 | .24 |